Truist Securities Maintains Buy on Climb Bio, Raises Price Target to $25

Benzinga Newsdesk www.benzinga.com Positive 82.7%

Neg 0% Neu 0% Pos 82.7%

Truist Securities analyst Danielle Brill maintains Climb Bio (NASDAQ:CLYM) with a Buy and raises the price target from $17 to $25.